WO2000069452A1 - Remedies for cancer and infection with helicobacter pylori and process for producing the same - Google Patents
Remedies for cancer and infection with helicobacter pylori and process for producing the same Download PDFInfo
- Publication number
- WO2000069452A1 WO2000069452A1 PCT/JP1999/002545 JP9902545W WO0069452A1 WO 2000069452 A1 WO2000069452 A1 WO 2000069452A1 JP 9902545 W JP9902545 W JP 9902545W WO 0069452 A1 WO0069452 A1 WO 0069452A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- parts
- licorice
- cancer
- lotus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
Definitions
- the present invention relates to a remedy for precancerous lesions, tumor markers—abnormal hyperplasia, cancer, or helicopaque H. pylori infection, and a method for producing the same.
- Background technology a remedy for precancerous lesions, tumor markers—abnormal hyperplasia, cancer, or helicopaque H. pylori infection, and a method for producing the same.
- Cancer is the leading or leading cause of death in Japan and Western Europe.
- cancer treatment methods include drug therapy, surgery, and radiation.
- the present invention has been made in view of the above-mentioned conventional problems, and is not limited to normal cancer, but also terminal cancer in which chemotherapy is not effective, and mutations or deletions in p53, which is a tumor suppressor gene, Furthermore, a therapeutic agent that is effective against Helicobacter pylori infection, And a method for producing the same.
- the present invention has revealed that at least half of the six crude drugs, Hanedan, Umeparasitic, White-flowered Snake Tongue, Yakuinin, Licorice, and Chichimo It has been found that the mixture of mothers has an antitumor effect, has tumor regression and prolongs the survival or prolongs the survival of cancer patients. It is based on the fact that it has been found that it inhibits bacterial growth.
- the present invention provides a mixture of at least a half-flowered lotus, a ume parasitic, a licorice, and a mother of six kinds of herbal medicines, a half-flowered lotus, a ume-parasitic, a white flower snake tongue grass, a good linden, a licorice, and a mother-in-law.
- the proportion of the weight of each crude drug is 0.3% to 63% for Haneda lotus, 0.3% to 63% for ume infestation, 0.3% to 60% for white flower, and 0.3% for 60%, and good jin.
- 3% to 60% Licorice is 0.3% to 60%
- Chimbo is 0.015% to 60%. Is to achieve.
- the crude extract of the water-soluble component or the alcohol-soluble component may be dried to form a powder.
- the above-mentioned semi-lotus consists of whole plant of Scutellaria barbate, and the ume parasite is Polyporaceae (Polyporaceae) Consisting of the whole components of Elfvingia applantaKars, the white-flowered snake tongue grass is a member of the genus Hedgotis diffusa Willd. Ma-youn Staph) is made from the seeds of the seeds except the seed coat, and the licorice is Glycyrrhiza uraknsis
- her mother may consist of rhizomes of Annemarrhena asaphodelodes Bunge.
- the invention of this production method is based on at least half-flowered lotus, ume-parasitic, licorice, and
- the above object is achieved by a method for producing a drug for treating cancer and helicopax-H. Pylori infection characterized by extracting one of a water-soluble component and an alcohol-soluble component with one of ethyl alcohol and ethyl alcohol. is there.
- the method for producing a remedy for cancer and Helicobacter pylori infection comprising: at least a half-lotus, ume-parasitic, licorice of the half-branch, ume parasitism, white-flowered snake tongue grass, good-for-all, licorice, and chichimo.
- one of the water-soluble component and the alcohol-soluble component may be extracted from the mixture of Chimo using hot water or ethyl alcohol.
- the method for producing a remedy for infectious disease of Helicobacter pylori as described above comprises at least a half of lotus, plum
- a water-soluble component and an alcohol-soluble component may be separately extracted from parasitism, licorice and tomochi with hot water or ethyl alcohol, and the extracts may be mixed.
- the method for producing a drug for treating cancer and Helicobacter pylori infection Based on 12 parts by weight of the semi-branch lotus, 8 parts by weight of ume parasite, 8 parts by weight of white flower snake tongue grass, 8 parts by weight of good jin, 3 parts by weight of licorice, 3 parts by weight of Chichimo, Among them, at least half-branch lotus, ume parasite, licorice, and tomochi are extracted with 300 to 500 parts by weight of hot water for 30 to 60 minutes, or alcohol-soluble components are extracted with ethyl alcohol. It may be extracted and filtered through a filter to obtain about 150 to 250 parts by weight of a crude extract.
- the crude extract of about 150 to 250 parts by weight is dried to obtain a powder of 2 to 5 parts by weight. It may be.
- the method comprises the steps of: One of the soluble component and the alcohol-soluble component may be extracted.
- the half-branch lotus comprises a whole plant of Scutellaria barbatae, and the ume parasite is Polyporaceae ) Consists of all the constituents of ElfVingia applantaKarst.
- White-snake snake tongue grass is composed of the whole plant of the moss family Hedgotis diffusaWilld.
- Ma-youn Staph may be made of seeds without seed coat, licorice may be made of roots of Glycyrrhiza uralensis Fischer, and tomato may be made of rhizome of Annemarrhena asaphodelodes Bunge.
- semi-ring lotus which is made up of semi-ring lotus, ume parasite and licorice, semi-lotus, ume parasite and licorice have anti-tumor effect independently in vitro.
- Hanedaren-to has a low tumor growth inhibitory effect on gastric cancer cell line MKN45 with wi1 dtypep53 (cancer suppressor gene) and KAT0- ⁇ which is a p53-deficient strain.
- Lotus has the strongest tumor growth inhibitory and cell death-inducing effects, followed by ume parasite and licorice. The cell death induced at that time is partially The Sith, mostly necrotic.
- Hanedarento inhibited the growth of MKN45 most strongly.
- the second inhibitor was KATO-III, which inhibited the proliferation of normal human dermal fibroblast cell lines the least.
- Haneda Rento it was found that the antitumor effect against p53-deficient strain was low. Therefore, a method to enhance the antitumor effect against p53-deficient strain is needed.
- the inventor has studied a method for enhancing the antitumor effect. It was found that Michimo had MKN45 and KATO-III cell growth inhibitory and cell death-inducing effects. In this case, the cell death is almost 100% apoptosis. Furthermore, compared to MKN45, she showed a significant difference in the growth inhibitory effect and the apoptosis-inducing effect on KATO-III, a p53-deficient strain. Tomochi morphologically expressed apoptotic bodies in cancer cells. Extraction of fragmented DNA from the mother-to-mother-added cancer cells and agarose gel electrophoresis revealed DNA ladder, and she found that the mother-of-mother induced cancer cells to die by apoptosis. In addition, she found that it released cytochrome C from mitochondria of cancer cells, activated intracellular caspases, and induced apoptosis.
- Chimo also has a synergistic antitumor effect against MKN 45, which has wi ldt pe p 53, and the combination of Hanedarento and Chimo's concentrations at that time is 8: 1. 4 to 1 worked most synergistically. From the above, we found that when Hanedayu and Chimo are combined, the most synergistic effect is basically 4 to 1. However, they also discovered that 8: 1 or 2: 1 is acceptable.
- licorice As described above, Hanjangren, Chimbo, ume parasite, and licorice each directly suppress cancer growth and cause cell death of cancer, but licorice has a weak effect of inducing cancer cell death. However, the cancer cell death-inducing effect of licorice is enhanced by a synergistic or additive effect with other components. In addition, white flower snake tongue grass enhances NK activity.
- the therapeutic agent of the present invention is effective for treating cancer, precancer, abnormally high tumor marker values, and Helicobacter pylori infection.
- the above-mentioned half-branch lotus, ume parasite, white flower snake tongue plant, good nin, licorice, and tomochi are all crude drugs, and water-soluble components are extracted from each small piece with hot water.
- the half-branch lotus is composed of a whole plant of a half-branch lotus (Scutellaria barbatae).
- the tongue grass is Futabamugra
- the average adult intake for the treatment of cancer is 80 ml of the crude extract or 600 to 500 Omg of the freeze-dried powder three times a day. If a stronger effect is expected, the crude extract may be taken in 2500 ml or its lyophilized powder up to 51 g once daily or in divided doses. It is possible to increase or decrease the amount of each crude drug in the above mixture of crude drugs.
- the weight of each crude drug per day before extraction is 0.1 to 50 g for half-branch lotus, 0.1 to 50 g for ume parasite, and 0.1 to 50 g for white flower snake tongue grass. It is possible to have a dosage of 0.1 to 50 g for jin, 0.1 to 30 g for licorice, and 0.05 to 50 g for Tomochi.
- the proportion of the weight of each crude drug ranges from 0.3% to 63% for Haneda lotus and 0.
- a mixture containing 3% to 6060%, licorice from 0.3% to 60%, and Chichimo from 0.015% to 60% is possible.
- the basic composition of the crude drug is half-branch lotus, ume parasite, white-flowered snake tongue grass, good-living seed, licorice, and tomochi. Absent.
- the basic formula is as follows: 12 g of half-branch lotus, 8 g of ume parasite, 8 g of white flower snake tongue grass, 8 g of good-looking jin, 3 g of licorice, 3 g of chinboshi It can be provided in a customized form.
- 120 parts by weight of semi-branch lotus, 80 parts by weight of ume parasite, 80 parts by weight of white flower snake tongue grass, 80 parts by weight of good liquor, 30 parts by weight of licorice, 30 parts by weight of Chichimo are 5,000 parts
- the crude extract was extracted with hot water for 30-60 minutes and filtered through a 1 mm filter.
- the alcohol extraction component may be extracted with ethyl alcohol.
- it may be dried or freeze-dried powder. It is also possible to pack the dried or freeze-dried powder into capsules, mix it with compatible non-influencing substances, or to make tablets by mechanical pressure.
- the water-soluble component extracted from hot water obtained from the above-mentioned half-branch lotus, plum infestation, white flower snake tongue grass, saccharin, licorice, and mother-to-child or ethyl alcohol-extracted component is orally administered.
- the component or one component may be administered enema, intraperitoneally, pleurally, or intravenously.
- Conditions or diseases that can be treated are cancer, precancerous, tumor marker-abnormal high value, Helicobacter pylori infection, and helicopacu-H. Pylori infection has adversely affected the disease state. (Muc osa as soci at ed l ymph oidtisue) One of 1 ymp homa.
- the crude extract is dried or freeze-dried powder to treat cancer and helicobacter pylori infection.
- the crude extract is taken at a dose of 600 to 500 Omg or the equivalent thereof 1 to 4 times a day until the cancer is reduced, regressed, or has a growth inhibitory effect. You can have a few rest days without taking it. If the effect is low, the powder can be added in a timely manner. If ethyl alcohol is extracted, the dose may be reduced, but in that case, about 75% of the dose should be administered. If the growth inhibitory effect appears, take it at intervals. If the tumor has regressed, continue for about a year.
- the crude extract is dried or freeze-dried into a powdered drug for treating cancer and helicopa-pylori infection 600 to 5000 mg, or the crude extract corresponding thereto. Is to take 1 to 4 times a day for 7 consecutive days. If helicopter H. pylori eradicates quickly, the dose can be reduced to one day. If eradication is required for a long time, it can be extended to one month. If ethyl alcohol is extracted, the dose may be reduced, but about 75% of the dose should be administered. If the growth inhibitory effect is observed, take it for each period. If symptoms of recurrence appear, resume taking the drug again. Industrial applicability
- the therapeutic agent of the present invention is useful not only for cancers for which chemotherapy is effective, but also for terminal cancers where chemotherapy is not effective, mutations or deletions in p53, which is a tumor suppressor gene, and also for Helicobacter pylori. It is also effective against bacterial infections.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
明 細 書 癌及びへリコパク夕—ピロリ菌感染症の治療薬、 及びその製造方法 技術分野 TECHNICAL FIELD Therapeutic agents for cancer and Helicopaque-H. Pylori infection, and methods for producing the same
この発明は、 前癌病変、 腫瘍マーカ—異常高値症、 癌、 あるいはへリコパク夕 一ピロリ菌感染症の治療薬、 及び、 その製造方法に関する。 背景の技術 The present invention relates to a remedy for precancerous lesions, tumor markers—abnormal hyperplasia, cancer, or helicopaque H. pylori infection, and a method for producing the same. Background technology
癌は、 日本及び西欧諸国での死亡原因の第 1位あるいは上位にある。 これに対 して癌の治療方法としては、 薬物療法、 外科手術、 放射線照射がある。 Cancer is the leading or leading cause of death in Japan and Western Europe. In contrast, cancer treatment methods include drug therapy, surgery, and radiation.
薬物療法の内、 化学療法が有効な癌の種類は限られており、 又、 化学療法が有 効な癌種であっても、 多くの末期癌の腫瘍退縮を齎すのは困難であり、 且つ、 患 者の癌抑制遺伝子である P 5 3に変異あるいは欠損があると、 化学療法が効き難 く、 治療が困難であるという問題点があった。 Of the pharmacotherapy, the types of cancer for which chemotherapy is effective are limited, and even for the types of cancer for which chemotherapy is effective, it is difficult to cause tumor regression for many terminal cancers, and However, if P53, which is a tumor suppressor gene of a patient, has a mutation or a defect, there is a problem that chemotherapy is not effective and treatment is difficult.
また、 例え、 化学療法が有効な場合でも、 副作用が強い場合が多く、 治療が困 難であったり、 有効性を示した後でも再発する問題点があつた。 Also, even if chemotherapy was effective, the side effects were often strong, and the treatment was difficult, and there was a problem that recurrence occurred even after showing efficacy.
更に、 近年、 へリコパクターピロリ菌感染症が、 胃かいよう、 更には、 胃癌の 原因となることが判明したが、 抗生物質以外に優れた治療手段がないという問題 点があった。 発明の開示 Furthermore, in recent years, it has been found that Helicobacter pylori infection causes stomach ulcers and even gastric cancer, but there is a problem that there is no better treatment than antibiotics. Disclosure of the invention
この発明は、 上記従来の問題点に鑑みてなされたものであって、 通常の癌のみ ならず、 化学療法が効かない末期癌、 癌抑制遺伝子である p 5 3に変異あるいは 欠損がある場合、 更には、 へリコパクターピロリ菌感染症にも有効な治療薬、 及 び、 その製造方法を提供することを目的とする。 The present invention has been made in view of the above-mentioned conventional problems, and is not limited to normal cancer, but also terminal cancer in which chemotherapy is not effective, and mutations or deletions in p53, which is a tumor suppressor gene, Furthermore, a therapeutic agent that is effective against Helicobacter pylori infection, And a method for producing the same.
この発明は、 本発明者による研究の結果、 半枝蓮、 梅寄生、 白花蛇舌草、 よく い仁、 甘草、 知母の 6種類の生薬のうち少なくとも半枝蓮、 梅寄生、 甘草、 知母 を混合したものに抗腫瘍効果があり、 癌患者の腫瘍退縮、 生存期間の延長あるい は延命効果があることを見い出し、 更に、 半枝蓮と知母は in vitroに於いてへリコ パクターピロリ菌の増殖を阻止することを発見したという事実に基づくものであ る。 As a result of research conducted by the inventor, the present invention has revealed that at least half of the six crude drugs, Hanedan, Umeparasitic, White-flowered Snake Tongue, Yakuinin, Licorice, and Chichimo It has been found that the mixture of mothers has an antitumor effect, has tumor regression and prolongs the survival or prolongs the survival of cancer patients. It is based on the fact that it has been found that it inhibits bacterial growth.
この発明は、 半枝蓮、 梅寄生、 白花蛇舌草、 よくい仁、 甘草、 知母の 6種類の 生薬のうち少なくとも半枝蓮、 梅寄生、 甘草、 知母を混合してなり、 前記各生薬 の重量の割合を、 半枝蓮が 0. 3%〜63%、 梅寄生が 0. 3%〜63%、 白花 蛇舌草が 0. 3%〜60%、 よくい仁が 0. 3%〜60%、 甘草が 0. 3%〜6 0%、 知母が 0. 0 1 5%〜60%としたことを特徴とする癌及びへリコバクタ —ピロリ菌感染症治療薬により上記目的を達成するものである。 The present invention provides a mixture of at least a half-flowered lotus, a ume parasitic, a licorice, and a mother of six kinds of herbal medicines, a half-flowered lotus, a ume-parasitic, a white flower snake tongue grass, a good linden, a licorice, and a mother-in-law. The proportion of the weight of each crude drug is 0.3% to 63% for Haneda lotus, 0.3% to 63% for ume infestation, 0.3% to 60% for white flower, and 0.3% for 60%, and good jin. 3% to 60%, Licorice is 0.3% to 60%, and Chimbo is 0.015% to 60%. Is to achieve.
前記癌及びへリコパクターピロリ菌感染症治療薬において、 前記半枝蓮、 梅寄 生、 白花蛇舌草、 よくい仁、 甘草、 知母の 6種類の生薬のうち少なくとも半枝蓮、 梅寄生、 甘草、 知母から得られる熱水抽出した水可溶成分、 及び、 ェチルアルコ —ル抽出したアルコール可溶成分の一方からなり、 前記各生薬の抽出前の重量の 割合を、 半枝蓮が 0. 3%〜63%、 梅寄生が 0. 3%〜63%、 白花蛇舌草が 0. 3%〜60%、 よくい仁が 0. 3%〜60%、 甘草が 0. 3%〜60%、 知 母が 0. 0 1 5%〜60%としてもよい。 In the above-mentioned remedy for cancer and Helicobacter pylori infection, at least half of the six crude drugs of the above-mentioned six kinds of crude drugs, namely, Hanedori, Umeyose, Shirakawa snake tongue grass, Oyakuin, Licorice, Chichimo Is composed of one of the water-soluble components extracted from hot water extracted from parasitism, licorice and tomochi, and the alcohol-soluble component extracted from ethyl alcohol. 0.3% to 63%, ume infestation 0.3% to 63%, white flower snake tongue grass 0.3% to 60%, good bonito 0.3% to 60%, licorice 0.3% ~ 60%, Chimo is 0.015% ~ 60%.
又、 前記癌及びへリコパクターピロリ菌感染症治療薬において、 前記水可溶成 分或いはアルコール可溶成分の粗抽出液を乾燥して形成された粉末としてもよい。 又、 前記癌及びへリコパク夕—ピロリ感染症治療薬において、 生薬状態で、 前 記半枝蓮は、 半枝蓮 (Scutellaria barbate) の全草よりなり、 梅寄生は、 サルノコ シカケ科 (Polyporaceae) コフキサルニコシカケ (Elfvingia applantaKars の全成 分よりなり、 白花蛇舌草は、 ァカネ科フタバムグラ (Hedgotis diffusa Willd.) の全 草よりなり、 よくい仁は、 はとむぎ( Coix lacryma-jobiし var. ma-youn Staph)の種子 から種皮を除いたものよりなり、 甘草は、 カンゾゥ (Glycyrrhiza uraknsis Further, in the therapeutic agent for cancer and Helicobacter pylori infection, the crude extract of the water-soluble component or the alcohol-soluble component may be dried to form a powder. In the above-mentioned remedy for cancer and helicopak-pylori infection, in a crude drug state, the above-mentioned semi-lotus consists of whole plant of Scutellaria barbate, and the ume parasite is Polyporaceae (Polyporaceae) Consisting of the whole components of Elfvingia applantaKars, the white-flowered snake tongue grass is a member of the genus Hedgotis diffusa Willd. Ma-youn Staph) is made from the seeds of the seeds except the seed coat, and the licorice is Glycyrrhiza uraknsis
Fischer ) の根からなり、 知母は、 ハナスゲ (Annemarrhena asaphodelodes Bunge) の根茎からなるようにしてもよい。 Fischer), and her mother may consist of rhizomes of Annemarrhena asaphodelodes Bunge.
又、 前記癌及びへリコパク夕一ピロリ感染症治療薬において、 前記半枝蓮が 1 2重量部、 梅寄生が 8重量部、 白花蛇舌草が 8重量部、 よくい仁が 8重量部、 甘 草が 3重量部、 知母が 3重量部を基本として、 これらの内少なくとも半枝蓮、 梅 寄生、 甘草、 知母を 3 0 0〜 5 0 0重量部の水で 3 0 ~ 6 0分間、 水可溶成分を 熱水抽出し、 あるいは、 エチルアルコールによりアルコール可溶成分を抽出し、 これをフィル夕—で濾過して約 1 5 0〜2 5 0重量部の粗抽出液を得るようにし てもよい。 Further, in the remedy for cancer and helicopaque Yuichi pylori infection, 12 parts by weight of the half-branch lotus, 8 parts by weight of ume parasite, 8 parts by weight of white flower snake tongue grass, 8 parts by weight of good jin Based on 3 parts by weight of licorice and 3 parts by weight of Chichimo, at least half of lotus, lotus plum, licorice, and licorice, 300 to 500 parts by weight of water are used. Extract the water-soluble component with hot water for one minute, or extract the alcohol-soluble component with ethyl alcohol, and filter it through a filter to obtain a crude extract of about 150 to 250 parts by weight. You may do so.
本製造方法の発明は、 半枝蓮、 梅寄生、 白花蛇舌草、 よくい仁、 甘草、 知母の 6種類の生薬のうち少なくとも半枝蓮、 梅寄生、 甘草、 知母から、 熱水及びェチ ルアルコールの一方により水可溶成分及びアルコール可溶成分の一方を抽出する ことを特徴とする癌及びへリコパク夕—ピロリ菌感染症治療薬の製造方法により 上記目的を達成するものである。 The invention of this production method is based on at least half-flowered lotus, ume-parasitic, licorice, and The above object is achieved by a method for producing a drug for treating cancer and helicopax-H. Pylori infection characterized by extracting one of a water-soluble component and an alcohol-soluble component with one of ethyl alcohol and ethyl alcohol. is there.
前記癌及びへリコパクターピロリ菌感染症治療薬の製造方法において、 前記半 枝蓮、 梅寄生、 白花蛇舌草、 よくい仁、 甘草、 知母のうち少なくとも半枝蓮、 梅 寄生、 甘草、 知母の混合体から、 熱水及びエチルアルコールの一方により水可溶 成分及びアルコ—ル可溶成分の一方を抽出するようにしてもよい。 The method for producing a remedy for cancer and Helicobacter pylori infection, comprising: at least a half-lotus, ume-parasitic, licorice of the half-branch, ume parasitism, white-flowered snake tongue grass, good-for-all, licorice, and chichimo. Alternatively, one of the water-soluble component and the alcohol-soluble component may be extracted from the mixture of Chimo using hot water or ethyl alcohol.
又、 前記癌及びへリコパクターピロリ菌感染症治療薬の製造方法において、 前 記半枝蓮、 梅寄生、 白花蛇舌草、 よくい仁、 甘草、 知母のうち少なくとも半枝蓮、 梅寄生、 甘草、 知母から、 個別に、 熱水及びエチルアルコールの一方により水可 溶成分及びアルコール可溶成分の一方を抽出し、 その抽出物を混合するようにし てもよい。 Further, in the method for producing a drug for treating cancer and Helicobacter pylori infectious disease, the method for producing a remedy for infectious disease of Helicobacter pylori as described above comprises at least a half of lotus, plum One of a water-soluble component and an alcohol-soluble component may be separately extracted from parasitism, licorice and tomochi with hot water or ethyl alcohol, and the extracts may be mixed.
更に、 前記癌及びへリコパクターピロリ菌感染症治療薬の製造方法において、 前記半枝蓮が 1 2重量部、 梅寄生が 8重量部、 白花蛇舌草が 8重量部、 よくい仁 が 8重量部、 甘草が 3重量部、 知母が 3重量部を基本として、 これらの内少なく とも半枝蓮、 梅寄生、 甘草、 知母を 3 0 0〜5 0 0重量部の水で 3 0〜6 0分間 熱水抽出し、 あるいは、 エチルアルコールによりアルコール可溶成分を抽出し、 これをフィル夕—で濾過して約 1 5 0〜2 5 0重量部の粗抽出液を得るようにし てもよい。 Further, in the method for producing a drug for treating cancer and Helicobacter pylori infection, Based on 12 parts by weight of the semi-branch lotus, 8 parts by weight of ume parasite, 8 parts by weight of white flower snake tongue grass, 8 parts by weight of good jin, 3 parts by weight of licorice, 3 parts by weight of Chichimo, Among them, at least half-branch lotus, ume parasite, licorice, and tomochi are extracted with 300 to 500 parts by weight of hot water for 30 to 60 minutes, or alcohol-soluble components are extracted with ethyl alcohol. It may be extracted and filtered through a filter to obtain about 150 to 250 parts by weight of a crude extract.
又、 前記癌及びへリコパクターピロリ菌感染症治療薬の製造方法において、 前 記約 1 5 0〜 2 5 0重量部の粗抽出液を乾燥して 2〜5重量部の粉末を得るよう にしてもよい。 Further, in the method for producing a drug for treating cancer and Helicobacter pylori infection, the crude extract of about 150 to 250 parts by weight is dried to obtain a powder of 2 to 5 parts by weight. It may be.
又、 前記癌及びへリコパクターピロリ感染症治療薬の製造方法において、 前記 半枝蓮、 梅寄生、 白花蛇舌草、 よくい仁、 甘草、 知母の、 各々の小切片から前記 水可溶成分及びアルコール可溶成分の一方を抽出するようにしてもよい。 Further, in the method for producing a therapeutic agent for treating cancer and Helicobacter pylori infection, the method comprises the steps of: One of the soluble component and the alcohol-soluble component may be extracted.
又、 前記癌及びへリコパクターピロリ感染症治療薬の製造方法において、 生薬 状態で、 前記半枝蓮は、 半枝蓮 (Scutellaria barbatae) の全草よりなり、 梅寄生は、 サルノコシカケ科 (Polyporaceae) コフキサルニコシカケ (ElfVingia applantaKarst.) の全成分よりなり、 白花蛇舌草は、 ァカネ科フタバムグラ (Hedgotis diffusaWilld.) の全草よりなり、 よくい仁は、 はとむぎ( Coix lacryma-jobi L. var. ma-youn Staph)の 種子から種皮を除いたものよりなり、 甘草は、 カンゾゥ (Glycyrrhiza uralensis Fischer ) の根からなり、 知母は、 ハナスゲ (Annemarrhena asaphodelodes Bunge) の根茎からなるようにしてもよい。 Further, in the method for producing a therapeutic drug for treating cancer and Helicobacter pylori infection, in a crude drug state, the half-branch lotus comprises a whole plant of Scutellaria barbatae, and the ume parasite is Polyporaceae ) Consists of all the constituents of ElfVingia applantaKarst., White-snake snake tongue grass is composed of the whole plant of the moss family Hedgotis diffusaWilld. Ma-youn Staph) may be made of seeds without seed coat, licorice may be made of roots of Glycyrrhiza uralensis Fischer, and tomato may be made of rhizome of Annemarrhena asaphodelodes Bunge.
前記半枝蓮、 梅寄生、 甘草からなる半枝蓮湯において、 半枝蓮、 梅寄生、 甘草 がそれそれ独立に i n V i t r oで、 抗腫瘍効果を持つ。 又、 半枝蓮湯は、 w i 1 d t y p e p 5 3 (癌抑制遺伝子) を持つ M K N 4 5という胃癌細胞株 や、 p 5 3欠損株である K A T 0— ΠΙに対し、 低濃度では腫瘍増殖抑制効果を、 高濃度では細胞死誘導効果を持つ。 腫瘍増殖抑制効果や細胞死誘導効果は半枝蓮 が最も強く、 次に梅寄生、 甘草が続く。 その際誘導される細胞死は一部アポ卜— シスで、 大部分壊死である。 In the above-mentioned semi-ring lotus, which is made up of semi-ring lotus, ume parasite and licorice, semi-lotus, ume parasite and licorice have anti-tumor effect independently in vitro. In addition, Hanedaren-to has a low tumor growth inhibitory effect on gastric cancer cell line MKN45 with wi1 dtypep53 (cancer suppressor gene) and KAT0-ΠΙ which is a p53-deficient strain. Has a cell death-inducing effect at high concentrations. Lotus has the strongest tumor growth inhibitory and cell death-inducing effects, followed by ume parasite and licorice. The cell death induced at that time is partially The Sith, mostly necrotic.
半枝蓮湯は MKN45の増殖を最も強く抑制した。 次に抑制したのが KATO — IIIで、 正常人皮膚線維芽細胞株の増殖に対しては抑制が最も弱かった。 しかし 半枝蓮湯の欠点として、 p 53欠損株に対する抗腫瘍効果が低いことがわかった c そこで p 53欠損株に対する抗腫瘍効果を増強する方法が必要である。 Hanedarento inhibited the growth of MKN45 most strongly. The second inhibitor was KATO-III, which inhibited the proliferation of normal human dermal fibroblast cell lines the least. However, as a disadvantage of Haneda Rento, it was found that the antitumor effect against p53-deficient strain was low. Therefore, a method to enhance the antitumor effect against p53-deficient strain is needed.
本発明者は、 前記抗腫瘍効果の増強方法を研究した。 そして知母が MKN45 と KATO— IIIの細胞の増殖抑制、 細胞死誘導効果を持つことが分かった。 この 場合、 前記細胞死はほとんど 100%がアポト—シスである。 しかも知母は MK N45に比べ、 p 53欠損株である KATO— IIIに対し、 有意差を持って増殖抑 制効果とアポトーシス誘導効果を示した。 知母は形態学的に癌細胞にアポトーシ ス小体を発現させた。 知母添加癌細胞の断片化した DN Aを抽出してァガロース ゲル電気泳動すると DNA l add e rが見られ、 知母はアポト—シスにより 癌細胞の死を誘導することを発見した。 また知母は癌細胞のミ トコンドリアから のチトクローム C遊離を起こし、 細胞内カスパーゼを活性化してアポト—シスを 誘導することを発見した。 The inventor has studied a method for enhancing the antitumor effect. It was found that Michimo had MKN45 and KATO-III cell growth inhibitory and cell death-inducing effects. In this case, the cell death is almost 100% apoptosis. Furthermore, compared to MKN45, she showed a significant difference in the growth inhibitory effect and the apoptosis-inducing effect on KATO-III, a p53-deficient strain. Tomochi morphologically expressed apoptotic bodies in cancer cells. Extraction of fragmented DNA from the mother-to-mother-added cancer cells and agarose gel electrophoresis revealed DNA ladder, and she found that the mother-of-mother induced cancer cells to die by apoptosis. In addition, she found that it released cytochrome C from mitochondria of cancer cells, activated intracellular caspases, and induced apoptosis.
次に半枝蓮湯に知母を添加することにより、 P 53欠損株である KATO— ΙΠ に対して、 知母が拮抗せずに、 半枝蓮湯の腫瘍増殖抑制効果や細胞死誘導効果を 高めるか検討した。 その結果知母は、 半枝蓮湯の抗腫瘍効果に対して拮抗を示さ ず、 増強した。 その際の半枝蓮湯と知母の濃度の組み合わせでは、 4対 1と 2対 1が最も効果を増強した。 半枝蓮湯と知母の濃度の組み合わせが 4対 1の時、 そ の混合物が、 KATO— ΙΠと MKN45に対し同程度の増殖抑制を有する抗腫瘍 効果を持つことを発見した。 このことから半枝蓮湯と知母の濃度比が 4対 1にな るように混合することにより、 p 53が欠損或いは変異した細胞株に対する抗腫 瘍効果が増強することを、 本発明者は発見した。 Next, by adding Chimo to Hanedarento, the inhibitory effect of Hanedarento on tumor growth and inducing cell death was achieved without Chimochi antagonizing P53-deficient KATO-ΙΠ. We considered whether to increase. As a result, Chimo showed no antagonism to the antitumor effect of Hanedarento, but enhanced it. At that time, the combination of the concentrations of Hanedarento and Chimo was the most effective when the ratio was 4: 1 and 2: 1. When the combination of Hanedarento and Chimo is 4: 1, the mixture was found to have an antitumor effect on KATO-ΙΠ and MKN45 with the same level of growth inhibition. From the above, it was confirmed that the antitumor effect against p53-deficient or mutated cell lines was enhanced by mixing Hanedarento and Chimomo in a concentration ratio of 4: 1. Has found.
また知母は wi l d t pe p 53を持つ MKN 45に対しても相乗的に 抗腫瘍効果を持ち、 その際の半枝蓮湯と知母の濃度の組み合わせでは、 8対 1と 4対 1が最も相乗的に作用した。 以上より半枝蓮湯と知母を組み合わせる場合、 最も相乗的に作用するのは、 基本的には 4対 1であることを発見した。 但し 8対 1や 2対 1でもかまわないことも発見した。 Chimo also has a synergistic antitumor effect against MKN 45, which has wi ldt pe p 53, and the combination of Hanedarento and Chimo's concentrations at that time is 8: 1. 4 to 1 worked most synergistically. From the above, we found that when Hanedayu and Chimo are combined, the most synergistic effect is basically 4 to 1. However, they also discovered that 8: 1 or 2: 1 is acceptable.
前記のように、 半枝蓮、 知母、 梅寄生、 甘草は、 各々直接的に癌増殖抑制、 癌 の細胞死をもたらすが、 甘草の癌細胞死誘導効果は弱い。 しかし、 甘草の癌細胞 死誘導効果は他の成分との相乗或いは相加効果で増強される。 又、 白花蛇舌草は N K活性を増強する。 As described above, Hanjangren, Chimbo, ume parasite, and licorice each directly suppress cancer growth and cause cell death of cancer, but licorice has a weak effect of inducing cancer cell death. However, the cancer cell death-inducing effect of licorice is enhanced by a synergistic or additive effect with other components. In addition, white flower snake tongue grass enhances NK activity.
更に、 半枝蓮と知母は i n V i t r 0に於いてへリコパクターピロリの増殖 を阻止することを発見した。 In addition, Haneda Lotus and Tomomo discovered that they inhibited the growth of Helicobacter pylori at inVitr0.
以上のことからこの発明の治療薬は、 癌、 前癌、 腫瘍マーカー異常高値症、 へ リコパクターピロリ感染症の治療に有効である。 From the above, the therapeutic agent of the present invention is effective for treating cancer, precancer, abnormally high tumor marker values, and Helicobacter pylori infection.
発明を実施するための最良の形態 BEST MODE FOR CARRYING OUT THE INVENTION
以下、 本発明の実施例を詳細に説明する。 Hereinafter, embodiments of the present invention will be described in detail.
まず、 半枝蓮 1 2 0重量部、 梅寄生 8 0重量部、 白花蛇舌草 8 0重量部、 よく い仁 8 0重量部、 甘草 3 0重量部、 知母 3 0重量部を 5 0 0 0重量部の水で 3 0 - 6 0分熱水抽出し、 1 mmのフィル夕一で濾過した粗抽出液 2 5 0 0重量部、 又は、 それを凍結乾燥粉末にしたもの 5 0重量部を、 本発明の癌及びへリコパク 夕一ピロリ感染症治療薬として得る。 First, 120 parts by weight of Haneda Lotus, 80 parts by weight of ume parasite, 80 parts by weight of white flower snake tongue grass, 80 parts by weight of coconut, 30 parts by weight of licorice, 30 parts by weight of Chimo 250 parts by weight of a crude extract obtained by extracting with hot water for 30-60 minutes with hot water for 30-60 minutes and filtering through a 1 mm filter or 50% by weight of freeze-dried powder Of the present invention as a therapeutic agent for cancer and helicopaque Yuichi pylori infection of the present invention.
前記半枝蓮、 梅寄生、 白花蛇舌草、 よくい仁、 甘草、 知母は、 いずれも生薬で あり、 各々の小切片から水可溶成分を熱水抽出する。 The above-mentioned half-branch lotus, ume parasite, white flower snake tongue plant, good nin, licorice, and tomochi are all crude drugs, and water-soluble components are extracted from each small piece with hot water.
又、 生薬状態で、 前記半枝蓮は、 半枝蓮 (Scutellaria barbatae) の全草よりなり、 梅寄生は、 サルノコシカケ科 (Polyporaceae) コフキサルニコシカケ (Elfvingia applantaKarst.) の全成分よりなり、 白花蛇舌草は、 ァカネ科フタバムグラ In a crude drug state, the half-branch lotus is composed of a whole plant of a half-branch lotus (Scutellaria barbatae). The tongue grass is Futabamugra
(Hedgotis diffusa Willd.) の全草よりなり、 よくい仁は、 はとむぎ( Coix lacryma- jobiし var. ma-youn Staph)の種子から種皮を除いたものよりなり、 甘草は、 カンゾ ゥ (Glvcyrrhiza uralensis Fischer ) の根からなり、 知母は、 ハナスゲ (Annemarrhena asaphodelodes Bunge) の根室力らなる。 (Hedgotis diffusa Willd.) Consists of whole plants, and good seeds consist of seeds of coix lacryma-jobi and var. Ma-youn Staph without seed coat. Licorice is Kanzo カ ン (Glvcyrrhiza uralensis). Fischer) The roots of my mother, Hanasuge (Annemarrhena asaphodelodes Bunge).
癌の治療のための平均的な成人の摂取量は、 1回あたり、 前記粗抽出液 80m 1又は凍結乾燥粉末 600から 500 Omgを 1日 3回とする。 より強力な効果 を期待する場合、 前記粗抽出液を 2500ml、 又は、 それを凍結乾燥粉末にし たもの 5 1 gまでを、 一日量として 1回或いは、 分割.して服用してもよい。 上記生薬の混合物の中でそれそれの生薬量を増減することが可である。 一日あ たり、 抽出前の各生薬の重量は、 半枝蓮が 0. 1から 50 g、 梅寄生が 0. 1か ら 50 g、 白花蛇舌草が 0. 1から 50 g、 よくい仁が 0. 1から 50 g、 甘草 が 0. 1から 30 g、 知母が 0. 05から 50 gの投与量にすることが可能であ る。 The average adult intake for the treatment of cancer is 80 ml of the crude extract or 600 to 500 Omg of the freeze-dried powder three times a day. If a stronger effect is expected, the crude extract may be taken in 2500 ml or its lyophilized powder up to 51 g once daily or in divided doses. It is possible to increase or decrease the amount of each crude drug in the above mixture of crude drugs. The weight of each crude drug per day before extraction is 0.1 to 50 g for half-branch lotus, 0.1 to 50 g for ume parasite, and 0.1 to 50 g for white flower snake tongue grass. It is possible to have a dosage of 0.1 to 50 g for jin, 0.1 to 30 g for licorice, and 0.05 to 50 g for Tomochi.
また各生薬の重量の割合は、 半枝蓮が 0. 3%から 63%まで、 梅寄生が 0. In addition, the proportion of the weight of each crude drug ranges from 0.3% to 63% for Haneda lotus and 0.
3%から 63%まで、 白花蛇舌草が 0. 3%から 60%まで、 よくい仁が 0.From 3% to 63%, white flower snake tongue grass from 0.3% to 60%, good kin.
3%から 6060%まで、 甘草が 0. 3%から 60%まで、 知母が 0. 015%か ら 60%まで含む混合成分で可である。 A mixture containing 3% to 6060%, licorice from 0.3% to 60%, and Chichimo from 0.015% to 60% is possible.
生薬の基本構成は半枝蓮、 梅寄生、 白花蛇舌草、 よくい仁、 甘草、 知母である が、 白花蛇舌草やよくい仁のどれか 1つ、 或いは両方を除いてもかまわない。 基本処方は、 半枝蓮 12 g、 梅寄生 8 g、 白花蛇舌草 8 g、 よくい仁 8 g、 甘 草 3 g、 知母 3 gを、 そのまま処方したり、 混合して煎じるばかりにした形で提 供することが可能である。 The basic composition of the crude drug is half-branch lotus, ume parasite, white-flowered snake tongue grass, good-living seed, licorice, and tomochi. Absent. The basic formula is as follows: 12 g of half-branch lotus, 8 g of ume parasite, 8 g of white flower snake tongue grass, 8 g of good-looking jin, 3 g of licorice, 3 g of chinboshi It can be provided in a customized form.
又、 前記のように、 半枝蓮 120重量部、 梅寄生 80重量部、 白花蛇舌草 80 重量部、 よくい仁 80重量部、 甘草 30重量部、 知母 30重量部を 5000重量 部の水で 30- 60分熱水抽出し、 1 mmのフィル夕—で濾過した粗抽出液 25 Also, as mentioned above, 120 parts by weight of semi-branch lotus, 80 parts by weight of ume parasite, 80 parts by weight of white flower snake tongue grass, 80 parts by weight of good liquor, 30 parts by weight of licorice, 30 parts by weight of Chichimo are 5,000 parts The crude extract was extracted with hot water for 30-60 minutes and filtered through a 1 mm filter.
00重量部を得ているが、 これは、 アルコール抽出成分をエチルアルコールによ り抽出してもよい。 又は、 それを乾燥或いは凍結乾燥粉末にしたものでもよい。 また前記乾燥或いは凍結乾燥した粉末をカプセルに詰めたり、 相性の良い非影響 性の物質と混ぜたり、 機械的な圧力で錠剤にすることも可能である。 前記半枝蓮、 梅寄生、 白花蛇舌草、 よくい仁、 甘草、 知母から得られる熱水抽 出した水可溶成分或いは、 エチルアルコール抽出した成分を通常は経口投与する が、 その全成分または一成分を注腸投与、 腹腔投与、 胸腔投与、 静脈内投与して もよい。 Although 100 parts by weight are obtained, the alcohol extraction component may be extracted with ethyl alcohol. Alternatively, it may be dried or freeze-dried powder. It is also possible to pack the dried or freeze-dried powder into capsules, mix it with compatible non-influencing substances, or to make tablets by mechanical pressure. Usually, the water-soluble component extracted from hot water obtained from the above-mentioned half-branch lotus, plum infestation, white flower snake tongue grass, saccharin, licorice, and mother-to-child or ethyl alcohol-extracted component is orally administered. The component or one component may be administered enema, intraperitoneally, pleurally, or intravenously.
治療を受けることができる病態或いは、 疾患は、 癌、 前癌、 腫瘍マーカ—異常 高値症、 へリコパクターピロリ菌感染症、 へリコパク夕—ピロリ菌感染が病態に 悪影響を与えている MAL T (Muc o s a as s o c i at ed l ymph o i d t i s u e ) 1 ymp h omaのうちのいずれかである。 Conditions or diseases that can be treated are cancer, precancerous, tumor marker-abnormal high value, Helicobacter pylori infection, and helicopacu-H. Pylori infection has adversely affected the disease state. (Muc osa as soci at ed l ymph oidtisue) One of 1 ymp homa.
本発明の癌及びへリコパク夕—ピロリ感染症治療薬の投与例は次の通りである 癌治療の場合、 前記粗抽出液を乾燥或いは凍結乾燥粉末にした癌及びヘリコバク 夕—ピロリ感染症治療薬 600〜500 Omg, 又は、 これに相当する前記粗抽 出液を、 1日 1から 4回、 癌が縮小、 退縮あるいは増殖抑制効果がでるまで服用 することを基本とする。 服用しない休養日を何日かもうけることができる。 効果 が低い場合、 適時その粉末を増量できる。 エチルアルコール抽出した場合は服用 量を減らしてもかまわないが、 その場合、 約 75%量を投与する。 増殖抑制効果 が出ている時はその期間ずつと服用する。 腫瘍が退縮した場合、 約 1年間続ける 再発の徴候が出てきたらまた服用を再開する。 Examples of administration of the therapeutic agent for cancer and helicopa-pylori infection of the present invention are as follows. In the case of cancer treatment, the crude extract is dried or freeze-dried powder to treat cancer and helicobacter pylori infection. Basically, the crude extract is taken at a dose of 600 to 500 Omg or the equivalent thereof 1 to 4 times a day until the cancer is reduced, regressed, or has a growth inhibitory effect. You can have a few rest days without taking it. If the effect is low, the powder can be added in a timely manner. If ethyl alcohol is extracted, the dose may be reduced, but in that case, about 75% of the dose should be administered. If the growth inhibitory effect appears, take it at intervals. If the tumor has regressed, continue for about a year.
へリコパクターピロリ菌感染症の治療は、 前記粗抽出液を乾燥或いは凍結乾燥 粉末にした癌及びへリコパク夕—ピロリ感染症治療薬 600〜5000mg, 又 は、 これに相当する前記粗抽出液を、 1日 1から 4回、 7日間連続服用すること を基本とする。 効果が早く出て、 へリコパクターピロリ菌が除菌できている場合 は、 服用日数を 1日間まで減らすことが可能である。 また除菌に長期間必要な場 合、 1か月まで延長できる。 エチルアルコール抽出した場合は服用量を減らして もかまわないが、 その場合、 約 75%量を投与する。 増殖抑制効果が出ている時 はその期間ずつと服用する。 再発の徴候が出てきたらまた服用を再開する。 産業上の利用可能性 For treatment of Helicobacter pylori infection, the crude extract is dried or freeze-dried into a powdered drug for treating cancer and helicopa-pylori infection 600 to 5000 mg, or the crude extract corresponding thereto. Is to take 1 to 4 times a day for 7 consecutive days. If helicopter H. pylori eradicates quickly, the dose can be reduced to one day. If eradication is required for a long time, it can be extended to one month. If ethyl alcohol is extracted, the dose may be reduced, but about 75% of the dose should be administered. If the growth inhibitory effect is observed, take it for each period. If symptoms of recurrence appear, resume taking the drug again. Industrial applicability
この発明の治療薬は、 化学療法が有効な癌のみならず、 化学療法が効かない末 期癌、 癌抑制遺伝子である p 5 3に変異あるいは欠損がある場合、 更には、 ヘリ コバク夕一ピロリ菌感染症にも有効である。 The therapeutic agent of the present invention is useful not only for cancers for which chemotherapy is effective, but also for terminal cancers where chemotherapy is not effective, mutations or deletions in p53, which is a tumor suppressor gene, and also for Helicobacter pylori. It is also effective against bacterial infections.
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP1999/002545 WO2000069452A1 (en) | 1999-05-17 | 1999-05-17 | Remedies for cancer and infection with helicobacter pylori and process for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP1999/002545 WO2000069452A1 (en) | 1999-05-17 | 1999-05-17 | Remedies for cancer and infection with helicobacter pylori and process for producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2000069452A1 true WO2000069452A1 (en) | 2000-11-23 |
Family
ID=14235700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1999/002545 Ceased WO2000069452A1 (en) | 1999-05-17 | 1999-05-17 | Remedies for cancer and infection with helicobacter pylori and process for producing the same |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2000069452A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005072532A1 (en) * | 2004-01-29 | 2005-08-11 | Jong-Hyun Nam | Natural tea having effects of hangover relief and liver function recovery and method for preparing the same |
| JP2010538093A (en) * | 2007-09-07 | 2010-12-09 | バイオノボ・インコーポレーテッド | Estrogenic extracts of the family Lamiaceae and its use |
| EP2222323A4 (en) * | 2007-11-19 | 2012-07-25 | Bionovo Inc | A process of making purified extract of scutellaria barbata d. don |
| US20130136812A1 (en) * | 2011-11-25 | 2013-05-30 | Wenchang Chiang | Alcohol extract of dehulled adlay seeds for treating gastric ulcer and/or stomach cancer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02300131A (en) * | 1989-05-15 | 1990-12-12 | Tsumura & Co | Carcinogenesis inhibitor |
| JPH03127736A (en) * | 1989-10-13 | 1991-05-30 | Koushindou:Kk | Pill preparation of specifically added chinese herbal remedy of cinnamon bark and powdered hoelen and production thereof |
| JPH10251156A (en) * | 1997-03-13 | 1998-09-22 | Shinichi Konuma | Extraction of pharmaceutically effective ingredient of mushroom |
-
1999
- 1999-05-17 WO PCT/JP1999/002545 patent/WO2000069452A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02300131A (en) * | 1989-05-15 | 1990-12-12 | Tsumura & Co | Carcinogenesis inhibitor |
| JPH03127736A (en) * | 1989-10-13 | 1991-05-30 | Koushindou:Kk | Pill preparation of specifically added chinese herbal remedy of cinnamon bark and powdered hoelen and production thereof |
| JPH10251156A (en) * | 1997-03-13 | 1998-09-22 | Shinichi Konuma | Extraction of pharmaceutically effective ingredient of mushroom |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005072532A1 (en) * | 2004-01-29 | 2005-08-11 | Jong-Hyun Nam | Natural tea having effects of hangover relief and liver function recovery and method for preparing the same |
| KR100718189B1 (en) | 2004-01-29 | 2007-05-16 | 남종현 | Natural tea effective for relieving hangovers and restoring liver function and its manufacturing method |
| CN1905803B (en) * | 2004-01-29 | 2011-06-22 | 南钟铉 | Natural tea having effects of hangover relief and liver function recovery and method for preparing the same |
| JP2010538093A (en) * | 2007-09-07 | 2010-12-09 | バイオノボ・インコーポレーテッド | Estrogenic extracts of the family Lamiaceae and its use |
| EP2222323A4 (en) * | 2007-11-19 | 2012-07-25 | Bionovo Inc | A process of making purified extract of scutellaria barbata d. don |
| US20130136812A1 (en) * | 2011-11-25 | 2013-05-30 | Wenchang Chiang | Alcohol extract of dehulled adlay seeds for treating gastric ulcer and/or stomach cancer |
| US8945638B2 (en) * | 2011-11-25 | 2015-02-03 | Joben Bio-Medical Co., Ltd. | Alcohol extract of dehulled adlay seeds for treating gastric ulcer and/or stomach cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gupta et al. | Momordica charantia Linn.(Karela): Nature’s silent healer | |
| Gilani et al. | A review of medicinal uses and pharmacological activities of Nigella sativa | |
| JP2948536B2 (en) | Methods for extracting biologically effective ingredient from compounded medicinal plant and purifying it, and their extract components | |
| Chawla et al. | A review of chemistry and biological activities of the genus Aerva--a desert plant | |
| EP3789032A1 (en) | Composition for preventing or treating cancer comprising extracts of anemone raddeana, lonicera species, and aralia elata containing high concentration of antitumor saponins, and method for preparing same | |
| CN100382822C (en) | Chinese medicine Sanyeqing for the prevention and treatment of tumors | |
| JP2012500776A (en) | ANTI-CANCER METHOD USING AN EXTRACT OF HANASGE ANEMARRHENAASPHODELOIDESBUNGE | |
| CN104523755B (en) | A kind of cockroach effective part and its preparation method and application | |
| KR101442141B1 (en) | Herbal medicine composition for anti-cancer and forms thereof | |
| US8945633B2 (en) | Pharmaceutical composition for preventing and treating inflammatory diseases containing an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient, and method for producing the fraction | |
| CN102772523B (en) | Bitter ganoderma composition for tumor treatment and preparation method thereof | |
| Kumar et al. | A comprehensive review on the chemical composition and pharmacological activities of ACACIA ARABICA | |
| Jitesh et al. | Anti inflammatory activity of Glycrrhiza glabra extract-an in vitro study | |
| CN104873446A (en) | A toothpaste with cinnamon oil | |
| EP2201957B1 (en) | Anti-aids, anti-tumour, immune-system-stimulating herbal composition and production method therefor | |
| WO2000069452A1 (en) | Remedies for cancer and infection with helicobacter pylori and process for producing the same | |
| AU2006209110B2 (en) | Pharmaceutical composition for treating nephropathy and healthy food comprising herb extracts | |
| KR100847440B1 (en) | Complex herbal medicine for the prevention and treatment of inflammatory diseases | |
| Mascolo et al. | Healing powers of aloes | |
| CN109010495A (en) | A kind of Chinese medicine composition and its preparation method and application | |
| AU2009258014A1 (en) | Anticancer methods using extracts of Anemarrhena asphodeloides Bunge | |
| Balakrishnan | Review on: Growing a Glass of Rich Immune Booster at Your Home: Triticum aestivum L.(Wheat Grass) Beneficial Effect on Health in this Pandemic Scenario | |
| CN101229348B (en) | Chinese traditional medicine compounds for treating tumour and preparing method thereof | |
| KR102165239B1 (en) | Hepatoprotective Composition Comprising Abeliophyllum Distichum Extract | |
| KR20220133573A (en) | Composition for Anticancer Comprising Cyrtomium falcatum extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 617911 Kind code of ref document: A Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase |